ResearchSafe

Crystagen (Crystagen (Immune Peptide Bioregulator))

Category: Immune Support. Status: Research compound (peptide bioregulator).

A short synthetic peptide bioregulator from the Khavinson family targeted at immune (thymus/lymphoid) tissue. It is used in the bioregulator community to support immune regulation and resilience, typically in short repeated courses.

How it works

As a signal peptide, it is proposed to enter cells and regulate gene expression in immune tissue, supporting normal thymic and lymphoid function, immune cell maturation, and balanced immune responses.

Key facts

  • Molecular weight: ~ (short peptide)
  • Half-life: Short (peptide)
  • Bioavailability: Oral (encapsulated) or subcutaneous
  • Storage: Room temperature (capsules) or refrigerate (injectable).

Dosing overview

  • Typical dose: ~1-2 capsules/day or short injectable courses
  • Frequency: Once daily
  • Duration: 10-30 day courses
  • Route: Oral capsule or subcutaneous

Protocol notes

  • Taken as short repeatable courses (often 10-30 days), a few times per year.
  • Oral encapsulated forms are taken once daily, usually on an empty stomach.
  • Often cycled seasonally for immune support.

Reported benefits

  • Immune regulation support
  • Thymic/lymphoid tissue support (proposed)
  • Immune resilience
  • Short course-based protocol
  • Part of bioregulator longevity systems

Possible side effects

  • Limited Western clinical data
  • Injection site reactions (injectable)
  • Unknown long-term effects

Research

  • Immune peptide bioregulators (2017): Reported to support thymic and lymphoid tissue function in regional research studies.

Compare Crystagen

Research and educational reference only. Not medical advice.